Screener
CytomX Therapeutics CTMX Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$20.67M-13,319% | -$18.25M-178% | -$26.51M-240% | -$14.23M-348% | -$154K+97.6% | ||
| $2.58M+80.1% | $4.71M+134% | $1.48M-21.5% | $1.38M-30.6% | $1.43M-24.0% | ||
| -$18.07M-14.7% | -$25.55M-21.4% | -$23.24M-16.8% | -$15.55M+25.0% | -$15.75M+19.4% | ||
| $0-100% | $0-100% | $201K+151% | —— | $27K-71.9% | ||
| —— | -$192.78M-730% | -$14.42M-195% | $0-100% | -$76.36M-455% | ||
| $511K-99.5% | $234.49M— | $16.64M+640% | $253K— | $93.55M+1,735% | ||
| —— | $16.16M+69.2% | -$21.02M— | -$14.86M— | $1.44M-79.7% | ||
| -$18.07M-14.5% | -$25.55M-20.7% | -$23.44M-17.3% | -$15.42M+25.7% | -$15.78M+19.7% |
FAQ
- How much cash does CytomX Therapeutics generate?
- CytomX Therapeutics (CTMX) generated -$82.4M in operating cash flow over the trailing twelve months.
- What is CytomX Therapeutics's free cash flow?
- After $228.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$82.5M over the trailing twelve months, down 6.2% year over year.
- Where does CytomX Therapeutics's cash flow data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
